

## Pixantrone (BBR 2778) Reference List

### Publications

1. Beggiolin G, Crippa L, Menta E, et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. *Tumori*. 2001;87(6):407-16.
2. Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. *Ann Oncol*. 2001;12(5):661-7.
3. Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphoma. *Haematologica*. 2003;88(8):888-94.
4. Borchmann P, Reiser M. Pixantrone – Novuspharma. *Idrugs*. 2003;6(5):486-90.
5. Dawson LK, Jodrell DI, Bowman A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. *Eur J Cancer*. 2000;36(18):2353-9.
6. Faivre S, Raymond E, Boige V, et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. *Clin Cancer Res*. 2001;7(1):43-50.
7. Krapcho AP, Petry ME, Getahun Z, et al. 6,9-bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10- diones, a novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. *J Med Chem*. 1994;37(6):828-37.
8. Skibo EB. BBR-2778 Novuspharma SpA. *Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs*. 2000;2(3):332-8.

### Abstracts

1. Bernareggi A, Allievi C, Hussein Z, et al. Population pharmacokinetics of Pixantrone in cancer patients. Poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November, 2003. Abstract 178.
2. Borchmann P, Engert A, Davite C, et al. Evaluation of cardiac events in patients treated with Pixantrone, a novel anthracycline derived drug. *Blood*. 2003;102(11):291b-2b. Abstract 4887.
3. Borchmann P, Schnell R, Morschhauser F, et al. A phase I study of Pixantrone (BBR 2778) in combination with cyclophosphamide, viscristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. Poster presentation at The American Society for Hematology Annual Meeting and Exposition, December, 2003. Abstract 2369.

## Pixantrone (BBR 2778) Reference List

4. Borchmann P, Morschhauser F, Schnell R, et al. Activity and safety of a new aza-anthracenedione BBR 2778 in patients with relapsed non-Hodgkin lymphomas. *Blood*. 2002;100(11):303b. Abstract 4752.
5. Cassin M, Crippa L, De Feudis P, et al. Molecular and histopathological evaluation of lack of Pixantrone induced cardiotoxicity as compared to Doxorubicin in mice. Poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November, 2003. Abstract A50.
6. Cassin M, De Feudis P, Consonni E, et al. Investigation of Pixantrone's mechanism of action on HS-Sultan human non-Hodgkin's lymphoma cells by cDNA microarray technology. Poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November, 2003. Abstract A65.
7. Cavalletti E, Crippa L, Melloni E, et al. BBR 2778, a novel aza-anthracenedione: preclinical toxicological evaluation. *Proceedings of the American Association for Cancer Research Annual Meeting*. 1993;34:374. Abstract 2227.
8. Crippa L, Franca S, Di Luccio E, Mainardi P, et al. The aza-anthracenedione Pixantrone (BBR 2778) confirms its reduced cardiotoxic potential vs. reference standards also in mouse pre-treated with anthracyclines. Poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November, 2003. Abstract C46.
9. Formento ML, Di Blasi P, Bernareggi A. Heart energy metabolism as a mechanism of cardiotoxicity: a comparison between BBR 2778 and mitoxantrone (MTX). *Eur J Pharm Sci*. 1998;6(Suppl 1):S53.
10. Giuliani FC, Beggiolin G, Pezzoni G, et al. 6,9-bis(aminoalkylamino) benzo [g]isoquinoline-5,10-diones, a novel class of chromophore-modified antitumor anthracenediones: synthesis and antitumor evaluation. *Proceedings of the American Association for Cancer Research Annual Meeting*. 1993;34:374. Abstract 2228.
11. Levine AM, Fayad L, Tulpule A, et al. Results of a Phase I/II trial with BBR-2778 (Pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL). Poster presentation at The American Society for Hematology Annual Meeting and Exposition, December, 2003. Abstract 2364.
12. Pezzoni G, Beggiolin G, Manzotti C, et al. BBR 2778: a novel aza-analog of anthracenediones endowed with preclinical anticancer activity. *Proceedings of the American Association for Cancer Research Annual Meeting*. 1993;34:373 Abstract 2226.